American Journal of Neuroradiology · 2017 · 24 citations · 15 references
MedicineOncologyRadiologyDiagnostic ImagingDiagnostic RadiologyNeuroradiologyBrain ImagingBrain TumorsGlioblastomaMagnetic Resonance ImagingNeuro-oncologic ImagingNeuro-oncology ImagingBrain Tumor DiagnosisContrast EnhancementDiagnostic ConfidenceLesion Border DelineationLesion Boundary DelineationLesion Enhancement AssessmentLesion VisualizationSafety In Magnetic Resonance Imaging
<h3>BACKGROUND AND PURPOSE:</h3> Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors. <h3>MATERIALS AND METHODS:</h3> This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2–14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from “poor” to “excellent.” Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site. <h3>RESULTS:</h3> For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (<i>P</i> < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain. <h3>CONCLUSIONS:</h3> The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.
15
Peter Marckmann, Lone Skov, Kristian Rossen et al. · Journal of the American Society of Nephrology · 2006 · 1.4K citations
Medicine, Nephrology, Radiology +10
Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging
Robert J. McDonald, Jennifer S. McDonald, David F. Kallmes et al. · Radiology · 2015 · 1.3K citations
Medicine, Neuroscience, Radiology +14
Tomonori Kanda, Kazunari Ishii, Hiroki Kawaguchi et al. · Radiology · 2013 · 1.3K citations